[go: up one dir, main page]

MXPA03011384A - Derivados de pirrolidina como inhibidores del factor xa. - Google Patents

Derivados de pirrolidina como inhibidores del factor xa.

Info

Publication number
MXPA03011384A
MXPA03011384A MXPA03011384A MXPA03011384A MXPA03011384A MX PA03011384 A MXPA03011384 A MX PA03011384A MX PA03011384 A MXPA03011384 A MX PA03011384A MX PA03011384 A MXPA03011384 A MX PA03011384A MX PA03011384 A MXPA03011384 A MX PA03011384A
Authority
MX
Mexico
Prior art keywords
factor
inhibitors
pyrrolidine derivatives
amelioration
inhibitor
Prior art date
Application number
MXPA03011384A
Other languages
English (en)
Inventor
Chan Chuen
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MXPA03011384A publication Critical patent/MXPA03011384A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La invencion se refiere a compuestos de la formula (I) (ver formula). a procedimientos para su preparacion, a composiciones farmaceuticas que los contienen y a su uso en medicina, particularmente su uso para mejorar un estado patologico para el cual esta indicado un inhibidor del Factor Xa.
MXPA03011384A 2001-06-08 2002-06-06 Derivados de pirrolidina como inhibidores del factor xa. MXPA03011384A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0114005.2A GB0114005D0 (en) 2001-06-08 2001-06-08 Chemical compounds
PCT/GB2002/002721 WO2002100830A1 (en) 2001-06-08 2002-06-06 Pyrrolidine derivatives as factor xa inhibitors

Publications (1)

Publication Number Publication Date
MXPA03011384A true MXPA03011384A (es) 2004-04-05

Family

ID=9916209

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03011384A MXPA03011384A (es) 2001-06-08 2002-06-06 Derivados de pirrolidina como inhibidores del factor xa.

Country Status (28)

Country Link
US (4) US7186717B2 (es)
EP (1) EP1395553B1 (es)
JP (1) JP4242274B2 (es)
KR (1) KR100877245B1 (es)
CN (1) CN1256324C (es)
AR (1) AR036086A1 (es)
AT (1) ATE289294T1 (es)
AU (1) AU2002311451B2 (es)
BR (1) BR0210207A (es)
CA (1) CA2449629A1 (es)
CO (1) CO5540285A2 (es)
CZ (1) CZ20033325A3 (es)
DE (1) DE60203006T2 (es)
DK (1) DK1395553T3 (es)
ES (1) ES2235050T3 (es)
GB (1) GB0114005D0 (es)
HU (1) HUP0400156A3 (es)
IL (1) IL159195A0 (es)
MX (1) MXPA03011384A (es)
MY (1) MY136859A (es)
NO (1) NO326689B1 (es)
NZ (1) NZ530004A (es)
PL (1) PL368082A1 (es)
PT (1) PT1395553E (es)
SI (1) SI1395553T1 (es)
TW (1) TWI298719B (es)
WO (1) WO2002100830A1 (es)
ZA (1) ZA200309367B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0114005D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0130705D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Chemical compounds
GB0228533D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Crystalline form
GB0228552D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Chemical compounds
US20050119266A1 (en) * 2003-10-01 2005-06-02 Yan Shi Pyrrolidine and piperidine derivatives as factor Xa inhibitors
PL1637141T3 (pl) * 2004-09-21 2012-04-30 Trobio Ab Stabilizowana kompozycja proteazy zawierająca proteazę serynową, pochodne morfoliny i odwracalne inhibitory tej proteazy serynowej
AU2005299693B2 (en) * 2004-10-26 2012-07-05 Janssen Pharmaceutica, N.V. Factor Xa compounds
WO2006110726A2 (en) * 2005-04-11 2006-10-19 Glaxo Group Limited Dosage formulations and methods of treatment and prevention
CN102380100A (zh) * 2005-09-22 2012-03-21 特罗比奥股份公司 稳定的蛋白酶组合物
JP5080476B2 (ja) * 2005-09-22 2012-11-21 トルービオ・アーベー 安定化プロテアーゼ組成物
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
TWI615390B (zh) * 2013-04-26 2018-02-21 賽諾菲公司 ５－氯－噻吩－２－羧酸［（ｓ）－２－［甲基－３－（２－側氧基－吡咯啶－１－基）－苯磺醯基胺基］－３－（４－甲基－哌嗪－１－基）－３－側氧基－丙基］－醯胺之酒石酸鹽
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92011A0 (en) 1988-10-19 1990-07-12 Abbott Lab Heterocyclic peptide renin inhibitors
DE4035961A1 (de) * 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4121947A1 (de) * 1991-07-03 1993-01-07 Basf Ag 2-(3-(4-amidino-phenyl))-propionsaeurederivate, ihre herstellung und verwendung
US5703208A (en) * 1994-06-17 1997-12-30 Corvas International, Inc. 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors
WO1998016523A2 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
BR9713921A (pt) 1996-12-13 2000-03-21 Rhone Poulenc Rorer Pharma Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
US6281227B1 (en) 1996-12-13 2001-08-28 Aventis Pharma Deutschland Gmbh Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
US6602864B1 (en) 1996-12-13 2003-08-05 Aventis Pharma Deutschland Gmbh Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
IL123986A (en) 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
ID23991A (id) * 1997-09-30 2000-06-14 Daiichi Seiyaku Co Turunan-turunan sulfonil
BR9907300A (pt) 1998-01-27 2000-10-24 Aventis Pharm Prod Inc Inibidores do fator xa oxoaza-heterociclila substituìdos
CN1298430A (zh) 1998-04-22 2001-06-06 昭和电工株式会社 表面被均匀氟化的粒状金属氧化物及其制造方法和用途
AU1926700A (en) 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase
EP1175405A4 (en) 1999-02-09 2002-05-15 Bristol Myers Squibb Co LACTAM INHIBITORS OF FACTOR Xa AND ASSOCIATED METHOD
KR20020004971A (ko) * 1999-03-16 2002-01-16 이경하 치환 프로린 유도체 및 이들을 함유하고 있는 의약 조성물
WO2000069465A1 (en) 1999-05-12 2000-11-23 Ono Pharmaceutical Co., Ltd. Anticancer agents containing ep1 antagonists as the active ingredient
SK1182002A3 (en) 1999-07-28 2002-11-06 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl compounds
EP1358178A2 (en) 2001-01-30 2003-11-05 Bristol-Myers Squibb Company Sulfonamide lactam inhibitors of factor xa
GB0114005D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0228552D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Chemical compounds
GB0228533D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Crystalline form

Also Published As

Publication number Publication date
AU2002311451B2 (en) 2006-03-02
PT1395553E (pt) 2005-06-30
IL159195A0 (en) 2004-06-01
JP2004537530A (ja) 2004-12-16
NO326689B1 (no) 2009-01-26
EP1395553B1 (en) 2005-02-16
DE60203006T2 (de) 2006-03-30
KR100877245B1 (ko) 2009-01-07
PL368082A1 (en) 2005-03-21
US20070142374A1 (en) 2007-06-21
DK1395553T3 (da) 2005-06-06
CZ20033325A3 (cs) 2004-08-18
JP4242274B2 (ja) 2009-03-25
US7429587B2 (en) 2008-09-30
US20070155745A1 (en) 2007-07-05
US7186717B2 (en) 2007-03-06
BR0210207A (pt) 2004-08-03
SI1395553T1 (en) 2005-06-30
EP1395553A1 (en) 2004-03-10
HK1063471A1 (en) 2004-12-31
US20070142375A1 (en) 2007-06-21
KR20040004706A (ko) 2004-01-13
TWI298719B (en) 2008-07-11
ES2235050T3 (es) 2005-07-01
HUP0400156A3 (en) 2008-10-28
WO2002100830A1 (en) 2002-12-19
AR036086A1 (es) 2004-08-11
GB0114005D0 (en) 2001-08-01
CN1538955A (zh) 2004-10-20
NO20035440D0 (no) 2003-12-05
NZ530004A (en) 2005-08-26
DE60203006D1 (de) 2005-03-24
CN1256324C (zh) 2006-05-17
ATE289294T1 (de) 2005-03-15
US7517879B2 (en) 2009-04-14
HUP0400156A2 (hu) 2004-07-28
CA2449629A1 (en) 2002-12-19
US7326785B2 (en) 2008-02-05
US20050107379A1 (en) 2005-05-19
MY136859A (en) 2008-11-28
ZA200309367B (en) 2004-08-02
CO5540285A2 (es) 2005-07-29

Similar Documents

Publication Publication Date Title
WO2002100886A8 (en) Pyrrolidin-2-one derivatives as inhibitors of factor xa
MY136859A (en) Pyrrolidine derivatives as factor xa inhibitors
PL357183A1 (en) Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor xa activity and pharmaceutical compositions containing them
MY144659A (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
GB0114286D0 (en) Nucleoside Derivatives
CA2499330A1 (en) New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
MXPA04004779A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.
CA2400268A1 (en) Pyrrolopyrimidinone derivatives, process of preparation and use
CA2407100A1 (en) 1-aroyl-piperidinyl benzamidines
MXPA02011425A (es) Derivados sustituidos de pirrolopiridinona utiles como inhibidores de fosfodiesterasa.
AU2001280438A1 (en) Substituted heterocyclic amides
MX2009005357A (es) Derivados de hidantoina usados como inhibidores de metaloproteinasas de matriz.
MXPA04004548A (es) Acidos heteroarilalalcanoicos substituidos y su uso como inhibidores de aldosa reductasa.
ECSP045378A (es) Derivados novedosos de diazabiciclononeno
TW200514772A (en) Novel tetrahydropyridine derivatives
NZ526913A (en) Inhibitors of cruzipain and other cysteine proteases
AP1787A (en) Novel perindopril salt and pharmaceutical compositions containing same.
DE602005019316D1 (en) Aromatische etherderivate als thrombin-hemmer
MXPA05010020A (es) Derivados de oxamida.
AU2003288233A1 (en) Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa
MXPA04005484A (es) Procedimiento de preparacion de derivados de equinocandina.
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments

Legal Events

Date Code Title Description
FG Grant or registration